Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai 201203, China.
The State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
Nucleic Acids Res. 2024 Jan 5;52(D1):D1508-D1518. doi: 10.1093/nar/gkad921.
Knowledge of the collective activities of individual plants together with the derived clinical effects and targeted disease associations is useful for plant-based biomedical research. To provide the information in complement to the established databases, we introduced a major update of CMAUP database, previously featured in NAR. This update includes (i) human transcriptomic changes overlapping with 1152 targets of 5765 individual plants, covering 74 diseases from 20 027 patient samples; (ii) clinical information for 185 individual plants in 691 clinical trials; (iii) drug development information for 4694 drug-producing plants with metabolites developed into approved or clinical trial drugs; (iv) plant and human disease associations (428 737 associations by target, 220 935 reversion of transcriptomic changes, 764 and 154121 associations by clinical trials of individual plants and plant ingredients); (v) the location of individual plants in the phylogenetic tree for navigating taxonomic neighbors, (vi) DNA barcodes of 3949 plants, (vii) predicted human oral bioavailability of plant ingredients by the established SwissADME and HobPre algorithm, (viii) 21-107% increase of CMAUP data over the previous version to cover 60 222 chemical ingredients, 7865 plants, 758 targets, 1399 diseases, 238 KEGG human pathways, 3013 gene ontologies and 1203 disease ontologies. CMAUP update version is freely accessible at https://bidd.group/CMAUP/index.html.
对单个植物的集体活动的了解，以及由此产生的临床效果和针对特定疾病的关联，对于基于植物的生物医学研究是有用的。为了提供补充现有数据库的信息，我们对 CMAUP 数据库进行了重大更新，该数据库之前在 NAR 中介绍过。此更新包括：(i) 与 5765 种植物的 1152 个靶点重叠的人类转录组变化，涵盖来自 20027 个患者样本的 74 种疾病；(ii) 691 项临床试验中 185 种植物的临床信息；(iii) 4694 种产生代谢物的产药植物的药物开发信息，这些代谢物已开发成批准或临床试验药物；(iv) 植物与人类疾病的关联（通过靶点的 428737 种关联，220935 种转录组变化的逆转，通过个体植物和植物成分的临床试验的 764 种和 154121 种关联）；(v) 在系统发育树中导航分类群的个体植物位置；(vi) 3949 种植物的 DNA 条形码；(vii) 通过既定的 SwissADME 和 HobPre 算法预测植物成分的人类口服生物利用度；(viii) 与上一版本相比，CMAUP 数据增加了 21-107%，涵盖了 60222 种化学物质、7865 种植物、758 个靶点、1399 种疾病、238 个 KEGG 人类途径、3013 个基因本体和 1203 个疾病本体。CMAUP 更新版本可在 https://bidd.group/CMAUP/index.html 免费获取。
